Patents by Inventor Lars Adolfsson
Lars Adolfsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11234828Abstract: A prosthesis for reconstruction of a distal radioulnar joint, after resection of a part of the ulna, includes a first prosthesis member, fixation members and a second prosthesis member. The first prosthesis member is configured for fixation to the distal end portion of the ulna. The fixation members are configured to extend into the radius via said distal end portion of the ulna for locking said distal end portion of the ulna to the radius. The second prosthesis member is configured for fixation to the ulna close to said distal end portion of the ulna. The second prosthesis member is also configured to extend into said space for being joined with the first prosthesis member in a manner which allows said first and second prosthesis members to at least pivot and rotate relative to each other.Type: GrantFiled: October 28, 2016Date of Patent: February 1, 2022Assignee: SWEMAC INNOVATION ABInventors: Henrik Hansson, Lars Oster, Michael Ullman, Lars Adolfsson
-
Patent number: 11123466Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non microporous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.Type: GrantFiled: August 27, 2018Date of Patent: September 21, 2021Assignee: ExThera Medical CorporationInventors: Robert S. Ward, Keith R. McCrea, Olle Larm, Lars Adolfsson
-
Patent number: 10639413Abstract: A blood filtration method, system, device and media for removing gram negative bacteria from the blood wherein the media includes a substrate coated with mannose optionally in constitution with substrate coated with heparin.Type: GrantFiled: August 2, 2018Date of Patent: May 5, 2020Assignee: Exthera Medical CorporationInventors: Keith McCrea, Robert Ward, Olle Larm, Lars Adolfsson
-
Publication number: 20190254833Abstract: A prosthesis (1) for reconstruction of a distal radioulnar joint after resection of a part of the ulna close to a distal end portion (U1) thereof, comprises a first prosthesis member (2), fixation means (3) and a second prosthesis member (4). The first prosthesis member (2) is configured for fixation to the distal end portion (U1) of the ulna. The fixation means (3) are configured to extend into the radius via said distal end portion of the ulna for locking said distal end portion of the ulna to the radius. The second prosthesis member (4) is configured for fixation to the ulna (U2) proximally of a space (US) which is defined between the distal end portion (U1) of the ulna and the ulna proximally of said space by the resection of said part of the ulna close to said distal end portion of the ulna.Type: ApplicationFiled: October 28, 2016Publication date: August 22, 2019Inventors: Henrik Hansson, Lars Oster, Michael Ullman, Lars Adolfsson
-
Publication number: 20190038826Abstract: A blood filtration method, system, device and media for removing gram negative bacteria from the blood wherein the media includes a substrate coated with mannose optionally in constitution with substrate coated with heparin.Type: ApplicationFiled: August 2, 2018Publication date: February 7, 2019Applicant: ExThera Medical CorporationInventors: KEITH MCCREA, ROBERT WARD, OLLE LARM, LARS ADOLFSSON
-
Publication number: 20180361050Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.Type: ApplicationFiled: August 27, 2018Publication date: December 20, 2018Applicant: EXTHERA MEDICAL CORPORATIONInventors: ROBERT S. WARD, Keith R. McCREA, Olle LARM, Lars ADOLFSSON
-
Patent number: 10086126Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non microporous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.Type: GrantFiled: June 30, 2016Date of Patent: October 2, 2018Assignee: ExThera Medical CorporationInventors: Robert S Ward, Keith R McCrea, Olle Larm, Lars Adolfsson
-
Patent number: 9669150Abstract: The present invention relates to a device for extracorporeal removal of harmful agents from blood or blood com-Components, comprising full length heparin immobilized on a solid substrate by covalent end point attachment. The present invention also relates to a method for extracorporeal removal of a harmful agent from mammalian blood or blood components. The present invention further relates to a process for covalent end point attachment of full length heparin to a solid substrate.Type: GrantFiled: January 15, 2014Date of Patent: June 6, 2017Assignee: EXTHERA MEDICAL CORPORATIONInventors: Olle Larm, Tomas Bergstrom, Jonas Axelsson, Lars Adolfsson, Robert S. Ward, Keith McCrae
-
Publication number: 20160331886Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.Type: ApplicationFiled: June 30, 2016Publication date: November 17, 2016Applicant: EXTHERA MEDICAL CORPORATIONInventors: ROBERT S. WARD, Keith R. McCrea, Olle Larm, Lars Adolfsson
-
Patent number: 9408962Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non microporous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.Type: GrantFiled: April 24, 2014Date of Patent: August 9, 2016Assignee: EXTHERA MEDICAL CORPORATIONInventors: Robert S. Ward, Keith R. McCrea, Olle Larm, Lars Adolfsson
-
Publication number: 20160101229Abstract: A blood filtration method, system, device and media for removing gram negative bacteria from the blood wherein the media includes a substrate coated with mannose optionally in constitution with substrate coated with heparin.Type: ApplicationFiled: December 17, 2015Publication date: April 14, 2016Applicant: EXTHERA MEDICAL CORPORATIONInventors: KEITH MCCREA, ROBERT WARD, OLLE LARM, LARS ADOLFSSON
-
Patent number: 8906883Abstract: A composition having an ionic complex of chitosan and a negatively charged polysaccharide, selected from the group consisting of heparin, heparan sulfate and dextran sulfate, for use in the treatment of mucositis in a mammalian subject, to a method of preventing or treating mucositis in a mammalian subject, by applying topically a composition having an ionic complex of chitosan and a negatively charged polysaccharide, selected from the group consisting of heparin, heparan sulfate and dextran sulfate. The composition further relates to a pharmaceutical composition for topical administration of an ionic complex of chitosan and heparin.Type: GrantFiled: June 10, 2010Date of Patent: December 9, 2014Assignee: Exthera ABInventors: Lars Adolfsson, Olle Larm, Anders Westermark
-
Publication number: 20140231357Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non microporous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.Type: ApplicationFiled: April 24, 2014Publication date: August 21, 2014Applicant: EXTHERA MEDICAL CORPORATIONInventors: Robert S Ward, Keith R. McCrea, Olle Larm, Lars Adolfsson
-
Patent number: 8758286Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.Type: GrantFiled: December 1, 2010Date of Patent: June 24, 2014Assignee: Exthera Medical CorporationInventors: Robert S Ward, Keith R. McCrea, Olle Larm, Lars Adolfsson
-
Publication number: 20140131276Abstract: The present invention relates to a device for extracorporeal removal of harmful agents from blood or blood com-Components, comprising full length heparin immobilized on a solid substrate by covalent end point attachment. The present invention also relates to a method for extracorporeal removal of a harmful agent from mammalian blood or blood components. The present invention further relates to a process for covalent end point attachment of full length heparin to a solid substrate.Type: ApplicationFiled: January 15, 2014Publication date: May 15, 2014Inventors: Olle LARM, Tomas Bergström, Jonas AXELSSON, Lars ADOLFSSON, Robert S. WARD, Keith MCCREA
-
Patent number: 8663148Abstract: The present invention relates to a device for extracorporeal removal of harmful agents from blood or blood components, comprising full length heparin immobilized on a solid substrate by covalent end point attachment. The present invention also relates to a method for extracorporeal removal of a harmful agent from mammalian blood or blood components. The present invention further relates to a process for covalent end point attachment of full length heparin to a solid substrate.Type: GrantFiled: June 18, 2008Date of Patent: March 4, 2014Assignee: Exthera Medical CorporationInventors: Olle Larm, Tomas Bergström, Jonas Axelsson, Lars Adolfsson, Robert S. Ward, Keith McCrea
-
Publication number: 20120077773Abstract: A composition having an ionic complex of chitosan and a negatively charged polysaccharide, selected from the group consisting of heparin, heparan sulfate and dextran sulfate, for use in the treatment of mucositis in a mammalian subject, to a method of preventing or treating mucositis in a mammalian subject, by applying topically a composition having an ionic complex of chitosan and a negatively charged polysaccharide, selected from the group consisting of heparin, heparan sulfate and dextran sulfate. The composition further relates to a pharmaceutical composition for topical administration of an ionic complex of chitosan and heparin.Type: ApplicationFiled: June 10, 2010Publication date: March 29, 2012Applicant: EXTHERA ABInventors: Lars Adolfsson, Olle Larm, Anders Westermark
-
Publication number: 20110184377Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.Type: ApplicationFiled: December 1, 2010Publication date: July 28, 2011Applicant: EXTHERA MEDICAL, LLCInventors: Robert S. WARD, Keith R. MCCREA, Olle Larm, Lars Adolfsson
-
Publication number: 20100249689Abstract: The present invention relates to a device for extracorporeal removal of harmful agents from blood or blood components, comprising full length heparin immobilized on a solid substrate by covalent end point attachment. The present invention also relates to a method for extracorporeal removal of a harmful agent from mammalian blood or blood components. The present invention further relates to a process for covalent end point attachment of full length heparin to a solid substrate.Type: ApplicationFiled: June 18, 2008Publication date: September 30, 2010Applicant: EXTHERA MEDICAL LLCInventors: Olle Larm, Tomas Bergström, Jones Axelsson, Lars Adolfsson, Robert S. Ward, Keith Mccrea
-
Patent number: 7573892Abstract: The invention relates to a switch or router (10) connected to and centrally situated adjacent to a voice over Internet protocol box (22) in a premise connected in a broadband network standard. It comprises an interface (14) to a category infrastructure for distribution of data to flats and offices in premises. The category infrastructure (12, 16) comprises four twisted wire pairs to every flat and office, whereby two pairs are utilized by the broadband standard. Voice over Internet is connected through a first cable interface (50) with multiple connections, and a second cable interface (60) connected and wired together in a registered jack (18, 52) with a category infrastructure. Two of the wire pairs (62) provide two voice over Internet protocol subscription possibilities to every flat and office and two of the broadband connections (64).Type: GrantFiled: July 11, 2005Date of Patent: August 11, 2009Assignee: B2 Bredband ABInventor: Lars Adolfsson